MEA Respiratory Tract Infection Treatment Market Trends | 2031

MEA Respiratory Tract Infection Treatment Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug (Antibiotics, NSAIDs, Cough Suppressants, Nasal Decongestants, and Others), Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), Route of Administration (Oral and Parenteral), Age Group (Pediatric and Adult), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and Country

  • Report Code : TIPRE00038996
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 201
Buy Now

The MEA respiratory tract infection treatment market size is expected to grow from US$ 2,092.80 million in 2023 to US$ 2,975.09 million by 2031 at a CAGR of 4.50%.

Market Insights and Analyst View:

Respiratory tract infections, or RTIs, are infections of the sinuses, throat, airways, or lungs. Though most RTIs resolve on their own, occasionally, a visit to your doctor may be necessary. The MEA respiratory tract infection treatment market report emphasizes the key factors driving the market and depicts the developments of prominent players. Key factors driving the market growth include the rising cases of respiratory infections in the Middle East, and increasing awareness related to respiratory tract infections. However, the lack of research focused on respiratory therapeutics hinders market growth. Further, the advent of antiviral treatment for MERS is expected to bring new MEA respiratory tract infection treatment market trends in the coming years.

Growth Drivers and Restraints:

The Middle East has been experiencing a rise in cases of respiratory infections, mainly driven by factors such as air pollution, smoking prevalence, crowded living conditions, and seasonal viral outbreaks. According to the NCBI data published in 2019, acute lower respiratory tract infections are a serious health issue that impacts nearly 15% of the Saudi population annually. Epidemiological research conducted during the past three decades suggests that most of these diseases are caused by viruses. As per the Saudi German Hospitals Group UAE, ~13% of adults and ~20% of children in Dubai are asthmatic, making it a serious health concern. Variables such as lifestyle decisions, genetic predisposition, and environmental triggers can be related to such a high incidence of asthma. The increasing burden of respiratory tract infections has created a demand for effective treatment options. Pharmaceutical companies capitalize on such growing needs by developing and offering innovative therapies. Moreover, with a focus on research and development, public–private partnerships, and awareness initiatives, they can play a crucial role in addressing challenges posed by respiratory infections in the Middle East.

The limited availability of comprehensive clinical trials, pharmacological evaluations, and real-world evidence focusing on respiratory medications in the MEA hinders the development of novel treatments, optimized treatment guidelines, and evidence-based practices that are tailored to the region's unique healthcare landscape. The unavailability of region-specific research data on the efficacy, safety, and cost-effectiveness of respiratory therapeutics poses challenges in designing targeted treatment strategies, deducing regional disease patterns, and optimizing patient outcomes. Furthermore, the lack of research studies may impede the identification of emerging respiratory pathogens, assessing treatment responses, and exploring optimal drug regimens tailored to the region's specific healthcare needs. The scarcity of research studies dedicated to respiratory therapeutics limits the MEA respiratory tract infection treatment market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

MEA Respiratory Tract Infection Treatment Market: Strategic Insights

mea-respiratory-tract-infection-treatment-market
Market Size Value inUS$ 2,092.80 million in 2023
Market Size Value byUS$ 2,975.09 million by 2031
Growth rateCAGR of 4.50% from 2023 to 2031
Forecast Period2023-2031
Base Year2023
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The MEA respiratory tract infection treatment market analysis has been carried out by considering the following segments: drugs, disease indication, route of administration, age group, and distribution channel. Based on drugs, the market is differentiated into antibiotics, NSAIDs, cough suppressants, nasal decongestants, and others. By disease indication, the MEA respiratory tract infection treatment market is segmented into upper respiratory tract infection and lower respiratory tract infection. In terms of route of administration, the market is differentiated into oral and parenteral. On the basis of age group, the market is classified into pediatric and adult. Based on distribution channel, the MEA respiratory tract infection treatment market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

In terms of drug, the antibiotics segment held the largest MEA respiratory tract infection treatment market share in 2023. The same is anticipated to register the highest CAGR during 2023–2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens. Antibiotics target and eliminate these harmful bacteria, reducing inflammation and promoting faster recovery. Commonly prescribed antibiotics for respiratory tract infections include penicillins, cephalosporins, macrolides, fluoroquinolones, and tetracyclines, and each of these has unique action mechanisms and bacterial targets.

Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023. It is further anticipated to register a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others. Conditions such as pneumonia, bronchitis, and bronchiolitis are categorized under the spectrum of LRTIs, typically exhibiting symptoms such as productive cough, chest discomfort, shortness of breath, and fever. Pneumonia, a severe LRTI, involves inflammation and infection of the lung tissue, leading to pulmonary consolidation (some areas of the lung or the complete organ) and impaired gas exchange.

By route of administration, the oral segment held a larger share of the MEA respiratory tract infection treatment market; the same segment is anticipated to register a higher CAGR during 2023–2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections. In addition to antibiotics, oral corticosteroids may reduce inflammation in severe asthma or chronic obstructive pulmonary disorder (COPD) exacerbations. Oral antiviral medications such as oseltamivir are utilized for treating viral respiratory infections such as influenza. The common advantages of the oral route include easy administration, patient compliance, and systemic drug distribution.

In terms of age group, the adult segment held a larger share of the MEA respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023–2031. The high prevalence of respiratory tract infections among children is a key factor driving the need for effective treatment options. Additionally, factors such as the surging awareness of the importance of early diagnosis and treatment of respiratory infections in children, advancements in medical technology leading to the development of new and more effective treatment options, and the growing focus on preventive healthcare measures are also contributing to the growth of the market for the pediatric segment.

In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023–2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications. These pharmacies are responsible for sourcing; storing; and dispensing antibiotics, antivirals, corticosteroids, and other respiratory infection treatments, alongside ensuring their safe and timely delivery to inpatient and outpatient settings in hospitals.

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Regional Analysis:

Thus, the growing awareness among the population about the importance of early diagnosis and treatment of respiratory infections is likely to contribute to the MEA respiratory tract infection treatment market growth in the coming years. The market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa. Saudi Arabia held the largest MEA respiratory tract infection treatment market share in 2023. The market in Saudi Arabia is experiencing significant growth owing to the elevated prevalence of respiratory tract infections in the country. Factors such as air pollution, smoking, and crowded living conditions contribute to the high incidence of respiratory infections in the country. The prevalence of COPD in the Kingdom is 2.4%; in addition, the prevalence of asthma in children and adults population ranges from 8% to 25% as per studies conducted over the past three decades. The Saudi Critical Care Society offers clinical education and training in respiratory treatment to Saudi Arabian healthcare practitioners in an extremely coordinated and well-structured manner. Thus, the increasing prevalence of respiratory infections, growing awareness about healthcare, and favorable initiatives by the government are driving the respiratory tract infection treatment market growth in Saudi Arabia.

Competitive Landscape and Key Companies:

The MEA respiratory tract infection treatment market forecast can help stakeholders plan their growth strategies. Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Orion Corporation, and Julphar are among the prominent players profiled in the MEA respiratory tract infection treatment market report. These companies focus on various strategies (including both organic and inorganic) to meet the burgeoning consumer demand and expand their product range in specialty portfolios. The major strategies adopted by the companies in the MEA respiratory tract infection treatment include new technology launches, existing product developments, and geographic expansions.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Drug, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are the driving factors for the MEA Respiratory Tract Infection Treatment Market?

Key factors driving the market growth include the rising cases of respiratory infections in the Middle East, and increasing awareness related to respiratory tract infections. However, the lack of research focused on respiratory therapeutics hinders market growth. Further, the advent of antiviral treatment for MERS is expected to bring new MEA respiratory tract infection treatment market trends in the coming years.

Who are the major players in the MEA Respiratory Tract Infection Treatment Market worldwide?

The MEA Respiratory Tract Infection Treatment Market majorly consists of the players such Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Orion Corporation, and Julphar.

Which segment is dominating the India Respiratory Tract Infection Treatment Market?

In terms of drug, the antibiotics segment held the largest MEA respiratory tract infection treatment market share in 2023. The same is anticipated to register the highest CAGR during 2023–2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens.

Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023. It is further anticipated to register a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others.

By route of administration, the oral segment held a larger share of the MEA respiratory tract infection treatment market; the same segment is anticipated to register a higher CAGR during 2023–2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections.

In terms of age group, the adult segment held a larger share of the MEA respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023–2031. The high prevalence of respiratory tract infections among children is a key factor driving the need for effective treatment options.

In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023–2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications.

What are Respiratory Tract Infection Treatment?

Respiratory tract infections, or RTIs, are infections of the sinuses, throat, airways, or lungs. Though most RTIs resolve on their own, occasionally, a visit to your doctor may be necessary. The MEA respiratory tract infection treatment market report emphasizes the key factors driving the market and depicts the developments of prominent players.

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. MEA Respiratory Tract Infection Treatment Market Landscape

4.1 Overview

4.2 PEST Analysis

5. MEA Respiratory Tract Infection Treatment Market – Key Market Dynamics

5.1 MEA Respiratory Tract Infection Treatment Market – Key Market Dynamics

5.2 Key Market Drivers

5.2.1 Rising Cases of Respiratory Infections in Middle East

5.2.2 Increasing Awareness Related to Respiratory Tract Infections

5.3 Key Market Restraints

5.3.1 Lack of Research Focused on Respiratory Therapeutics

5.4 Key Market Opportunities

5.4.1 Surge in Demand for OTC Products to Treat Respiratory Infections

5.5 Future Trends

5.5.1 Advent of Antiviral Treatment for MERS

5.6 Impact of Drivers and Restraints:

6. MEA Respiratory Tract Infection Treatment Market Analysis

6.1 MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023–2031

7. MEA Respiratory Tract Infection Treatment Market Analysis – by Drugs

7.1 Antibiotics

7.1.1 Overview

7.1.2 Antibiotics: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.2 NSAIDs

7.2.1 Overview

7.2.2 NSAIDs: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Cough Suppressants

7.3.1 Overview

7.3.2 Cough Suppressants: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Nasal Decongestants

7.4.1 Overview

7.4.2 Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

8. MEA Respiratory Tract Infection Treatment Market Analysis – by Disease Indication

8.1 Lower Respiratory Tract Infection

8.1.1 Overview

8.1.2 Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

8.2 Upper Respiratory Tract Infection

8.2.1 Overview

8.2.2 Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

9. MEA Respiratory Tract Infection Treatment Market Analysis – by Route Of Administration

9.1 Oral

9.1.1 Overview

9.1.2 Oral: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

9.2 Parenteral

9.2.1 Overview

9.2.2 Parenteral: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

10. MEA Respiratory Tract Infection Treatment Market Analysis – by Age Group

10.1 Pediatrics

10.1.1 Overview

10.1.2 Pediatrics: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

10.2 Adults

10.2.1 Overview

10.2.2 Adults: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

11. MEA Respiratory Tract Infection Treatment Market Analysis – by Distribution Channel

11.1 Hospital Pharmacies

11.1.1 Overview

11.1.2 Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

11.2 Retail Pharmacies

11.2.1 Overview

11.2.2 Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

11.3 Online Pharmacies

11.3.1 Overview

11.3.2 Online Pharmacies: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

12. MEA Respiratory Tract Infection Treatment Market – Country Analysis

12.1 Middle East and Africa

12.1.1 MEA Respiratory Tract Infection Treatment Market Breakdown by Countries

12.1.2 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis – by Country

12.1.3 MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2030

12.1.3.1 MEA Respiratory Tract Infection Treatment Market Revenue and Forecast and Analysis – by Country

12.1.3.2 Saudi Arabia

12.1.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

12.1.3.3.1 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs

12.1.3.3.2 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication

12.1.3.3.3 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration

12.1.3.3.4 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group

12.1.3.3.5 Saudi Arabia: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

12.1.3.4 South Africa

12.1.3.5 South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

12.1.3.5.1 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs

12.1.3.5.2 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication

12.1.3.5.3 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration

12.1.3.5.4 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group

12.1.3.5.5 South Africa: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

12.1.3.6 UAE

12.1.3.7 UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

12.1.3.7.1 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs

12.1.3.7.2 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication

12.1.3.7.3 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration

12.1.3.7.4 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group

12.1.3.7.5 UAE: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

12.1.3.8 Rest of MEA

12.1.3.9 REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

12.1.3.9.1 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Drugs

12.1.3.9.2 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Disease Indication

12.1.3.9.3 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Route Of Administration

12.1.3.9.4 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Age Group

12.1.3.9.5 REST of MEA: MEA Respiratory Tract Infection Treatment Market Breakdown by Distribution Channel

13. Company Profiles

13.1 Abbott Laboratories

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Teva Pharmaceutical Industries Ltd

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Sanofi SA

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Boehringer Ingelheim International GmbH

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 AstraZeneca Plc

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Alembic Pharmaceuticals Ltd

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 GSK Plc

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Novartis AG

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 F. Hoffmann-La Roche Ltd

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Gulf Pharmaceutical Industries Co

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

List of Tables

Table 1. MEA Respiratory Tract Infection Treatment Market Segmentation

Table 2. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs

Table 3. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication

Table 4. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration

Table 5. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group

Table 6. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 7. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Country

Table 8. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs

Table 9. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication

Table 10. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration

Table 11. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group

Table 12. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 13. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs

Table 14. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication

Table 15. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration

Table 16. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group

Table 17. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 18. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs

Table 19. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication

Table 20. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration

Table 21. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group

Table 22. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 23. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Drugs

Table 24. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Disease Indication

Table 25. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Route Of Administration

Table 26. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Age Group

Table 27. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 28. Glossary of Terms, MEA Respiratory Tract Infection Treatment Market

List of Figures

Figure 1. MEA Respiratory Tract Infection Treatment Market Segmentation, by Country

Figure 2. PEST Analysis

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. MEA Respiratory Tract Infection Treatment Market Revenue (US$ Million), 2023–2031

Figure 5. MEA Respiratory Tract Infection Treatment Market Share (%) – by Drugs, 2023 and 2031

Figure 6. Antibiotics: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 7. NSAIDs: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 8. Cough Suppressants: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 9. Nasal Decongestants: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 10. MEA Respiratory Tract Infection Treatment Market Share (%) – by Disease Indication, 2023 and 2031

Figure 11. Lower Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 12. Upper Respiratory Tract Infection: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 13. MEA Respiratory Tract Infection Treatment Market Share (%) – by Route Of Administration, 2023 and 2031

Figure 14. Oral: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 15. Parenteral: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 16. MEA Respiratory Tract Infection Treatment Market Share (%) – by Age Group, 2023 and 2031

Figure 17. Pediatrics: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 18. Adults: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 19. MEA Respiratory Tract Infection Treatment Market Share (%) – by Distribution Channel, 2023 and 2031

Figure 20. Hospital Pharmacies: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 21. Retail Pharmacies: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 22. Online Pharmacies: MEA Respiratory Tract Infection Treatment Market– Revenue and Forecast to 2031 (US$ Million)

Figure 23. MEA Respiratory Tract Infection Treatment Market Breakdown by Key Countries, 2023 and 2031 (%)

Figure 24. MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2030(US$ Million)

Figure 25. Saudi Arabia: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

Figure 26. South Africa: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

Figure 27. UAE: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

Figure 28. REST of MEA: MEA Respiratory Tract Infection Treatment Market – Revenue and Forecast to 2031 (US$ Million)

The List of Companies - MEA Respiratory Tract Infection Treatment Market

  1. Abbott Laboratories
  2. AstraZeneca plc
  3. Alembic Pharmaceuticals Ltd.
  4. Boehringer Ingelheim International GmbH
  5. GlaxoSmithKline plc
  6. Teva Pharmaceutical Industries Ltd
  7. Novartis AG
  8. F. Hoffmann-La Roche AG
  9. Sanofi S.A.
  10. Orion Corporation
  11. Julphar

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to MEA Respiratory Tract Infection Treatment Market